IL4-lytic(L)

General Information


DRACP ID  DRACP01377

Peptide Name   IL4-lytic(L)

Sequence  KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK

Sequence Length  33

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
BXPC-3 Pancreatic ductal adenocarcinoma Carcinoma IC50=3.2±0.4μM WST-8 assay 72h Patent
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=5.6±0.5μM WST-8 assay 72h Patent
A172 Glioblastoma Blastoma IC50=3.8±1.1μM WST-8 assay 72h Patent
KCCT873 Not available Not available IC50=4.6±0.1μM WST-8 assay 72h Patent
U251 Astrocytoma Carcinoma IC50=3.7±0.1μM WST-8 assay 72h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  PE: IC50>20μM; HEK293T: IC50=7.2±0.7μM; WI-38: IC50=9.8±0.8μM

Target  Interleukin-4 (IL4) Receptor

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01377

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C184H338N54O38

Absent amino acids  ACEHMPSTVWY

Common amino acids  L

Mass  448604

Pl  12.36

Basic residues  13

Acidic residues  1

Hydrophobic residues  14

Net charge  12

Boman Index  -5140

Hydrophobicity  -34.24

Aliphatic Index  153.64

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0319336 A1

Patent Title  Selective anticancer chimeric peptide.

Other Iinformation  Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013

Other Published ID  CN102238965A  EP2370107A2  WO2010064207A2  WO2010064207A3 




DRACP is developed by Dr.Zheng's team.